Stoke Therapeutics, Inc. STOK
26.99 USD +0.51 (+1.93%)
At closeNov 3, 2026, 4:33 PM EST
26.99 0.00 0.00%
After hours · Nov 3, 4:33 PM ET
26.63 Day range 27.51
20.32 52-week range 40.22
- YTD
- -14.97%
- 1 year
- +3.41%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 46.38 +71.9% upside
Now 26.99
- Target (low)
- 35.00
- Target (mean)
- 46.38
- Target (high)
- 60.00
Ratings (0m) 14 14 buy · 0 hold · 0 sell
- Strong buy2
- Buy12
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 14
- 1 month ago 14
- 2 months ago 14
- 3 months ago 14
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.97033 | -1.30 – -0.70 | -0.97 | -0.0% | 7.15M | +409.9% | 12 |
| Next quarter | -1.10 | -1.43 – -0.64 | -0.79 | -39.5% | 6.80M | +9.2% | 6 |
| Current year | -4.03 | -4.29 – -3.91 | -0.12 | -3258.3% | 35.42M | -80.8% | 7 |
| Next year | -3.77 | -5.00 – -2.55 | -4.03 | +6.6% | 45.13M | +27.4% | 12 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 4, 2026 | Guggenheim | Reiterated | Buy | Buy |
| Aug 4, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Aug 4, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Aug 4, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Jul 13, 2026 | Goldman Sachs | Initiated | — | Buy |
| May 11, 2026 | BTIG | Reiterated | Buy | Buy |
| Mar 20, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Mar 19, 2026 | BTIG | Reiterated | Buy | Buy |
| Mar 18, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Mar 18, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Mar 17, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Mar 17, 2026 | Needham | Maintained | Buy | Buy |
| Feb 24, 2026 | Wolfe Research | Initiated | — | Outperform |
| Jan 12, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Jan 5, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Jan 5, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Dec 15, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 5, 2025 | Canaccord Genuity | Maintained | Buy | Buy |
| Nov 5, 2025 | Wedbush | Maintained | Outperform | Outperform |
| Nov 5, 2025 | BTIG | Reiterated | Buy | Buy |
| Nov 3, 2025 | JP Morgan | Maintained | Neutral | Neutral |
| Oct 13, 2025 | BTIG | Maintained | Buy | Buy |
| Oct 10, 2025 | Needham | Maintained | Buy | Buy |
| Aug 13, 2025 | Chardan Capital | Maintained | Buy | Buy |
| Aug 13, 2025 | Wedbush | Maintained | Outperform | Outperform |
| Jul 18, 2025 | Jefferies | Initiated | — | Buy |
| Jul 1, 2025 | Needham | Reiterated | Buy | Buy |
| May 14, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Apr 9, 2025 | Needham | Reiterated | Buy | Buy |
| Mar 19, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |